Systemic drug therapy for restenosis: "Déjà vu all over again"

Circulation

Volumn 106, Issue 18, 2002, Pages 2296-2298

  Faxon, David P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Drugs; Editorials; Restenosis; Stents

Indexed keywords

CILOSTAZOL; EVEROLIMUS; FOLIC ACID; PACLITAXEL; PEMIROLAST; PLATELET DERIVED GROWTH FACTOR; PROBUCOL; RAPAMYCIN; TRANILAST; TROGLITAZONE; VALSARTAN;

ANGIOPLASTY; ARTERY INTIMA PROLIFERATION; BYPASS SURGERY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CORONARY ARTERY DILATATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; EDITORIAL; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOSIS;

BRACHYTHERAPY; CORONARY RESTENOSIS; DRUG IMPLANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 0037195148     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000038412.38399.D5     Document Type: Editorial

References (13)

1. Farb A, John M, Acampo E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379-2384.
2. Marx SO, Marks AR. The development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855.
3. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
4. Mody VH, Durairaj A, Mehra AO. Pharmacological approaches to prevent restenosis. In Faxon DP, ed. Restenosis: A Guide to Therapy. London, UK: Martin Durnitz: 2001:97-112.
5. Lafont A, Faxon DP. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res. 1998;39:50-59.
6. Grube E, Silber SM, Eugene K, et al. Taxus I: Prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. Circulation. 2001;104(suppl II):II-463. Abstract.
7. Gershlick AH, Descheerder I, Belgium L, et al. Local drug delivery to inhibit coronary artery restenosis: Data From the ELUTES (EvaLUation of pacliTaxel Eluting Stent) clinical trial. Circulation. 2001;104(suppl II):II-416. Abstract.
8. Park SJ, Shim WH, Ho DS, et al. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial. Circulation. 2001;104(suppl II):II-464. Abstract.
9. Grube E, Hauptmann K, Colombo A, et al. SCORE trial interim safety results: Despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent. J Am Coll Cardiol. 2002;39:38A. Abstract.
10. Lafont A, Topol E, eds. Arterial Remodeling: A Critical Factor in Restenosis. Boston, Mass: Kluwer Academic Publishers; 1997.
11. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
12. Hung J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Atheroscler Thromb Vasc Biol. 2002;22:745-751.
13. Faxon DP, ed. Restenosis: A Guide To Therapy. London, UK: Martin Dunitz; 2001.